Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$453M |
| 2 |
CELG
Celgene Corp
CELG
|
+$391M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$389M |
| 4 |
GE Aerospace
GE
|
+$378M |
| 5 |
Johnson & Johnson
JNJ
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$307M |
| 2 |
Costco
COST
|
+$279M |
| 3 |
Lowe's Companies
LOW
|
+$273M |
| 4 |
Microsoft
MSFT
|
+$230M |
| 5 |
Chevron
CVX
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.07% |
| 2 | Technology | 14.35% |
| 3 | Financials | 11.23% |
| 4 | Consumer Discretionary | 9.93% |
| 5 | Real Estate | 8.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BSCJ
2251
DELISTED
Invesco BulletShares 2019 Corporate Bond ETF
BSCJ
| $2.33M | ﹤0.01% |
110,394
-71,806
| -39% | -$1.51M |
|
|
AVDL
2252
DELISTED
Avadel Pharmaceuticals
AVDL
| $2.32M | ﹤0.01% |
802,606
+144,270
| +22% | +$248K |
|
2253
BGC Group
BGC
$5.2B
| $2.32M | ﹤0.01% |
443,520
+83,664
| +23% | +$434K |
|
|
GPOR
2254
DELISTED
Gulfport Energy Corp.
GPOR
| $2.32M | ﹤0.01% |
472,200
+455,232
| +2,683% | +$2.9M |
|
2255
Cigna
CI
$73.5B
| $2.31M | ﹤0.01% |
14,659
-813,900
| -98% | -$128M |
|
2256
ICU Medical
ICUI
$4.58B
| $2.29M | ﹤0.01% |
+9,100
| New | +$2.11M |
|
|
FLNT
2257
Fluent
FLNT
$129M
| $2.29M | ﹤0.01% |
70,851
+64,933
| +1,097% | +$2.29M |
|
2258
Townsquare Media
TSQ
$104M
| $2.29M | ﹤0.01% |
425,037
-22,141
| -5% | -$124K |
|
|
SFIX
2259
Stitch Fix
SFIX
$487M
| $2.27M | ﹤0.01% |
71,100
+52,000
| +272% | +$1.4M |
|
|
RNWK
2260
DELISTED
RealNetworks Inc
RNWK
| $2.27M | ﹤0.01% |
1,192,423
+18,300
| +2% | +$41.7K |
|
|
SBBX
2261
DELISTED
SB One Bancorp Common Stock
SBBX
| $2.25M | ﹤0.01% |
100,900
+10,900
| +12% | +$246K |
|
|
HA
2262
DELISTED
Hawaiian Holdings, Inc.
HA
| $2.25M | ﹤0.01% |
82,100
+26,600
| +48% | +$722K |
|
2263
State Street SPDR Portfolio Long Term Treasury ETF
SPTL
$10.8B
| $2.25M | ﹤0.01% |
59,000
+10,100
| +21% | +$369K |
|
2264
Autohome
ATHM
$2.65B
| $2.24M | ﹤0.01% |
+26,200
| New | +$2.61M |
|
2265
Hecla Mining
HL
$11.9B
| $2.24M | ﹤0.01% |
1,244,290
-179,300
| -13% | -$328K |
|
|
ACRE
2266
Ares Commercial Real Estate
ACRE
$264M
| $2.23M | ﹤0.01% |
149,800
-150,068
| -50% | -$2.27M |
|
|
BAS
2267
DELISTED
Basis Energy Services, Inc.
BAS
| $2.22M | ﹤0.01% |
1,169,900
+538,800
| +85% | +$1.4M |
|
2268
Comscore
SCOR
$108M
| $2.22M | ﹤0.01% |
+21,500
| New | +$4.6M |
|
2269
Curis
CRIS
$3.91M
| $2.22M | ﹤0.01% |
2,979
+509
| +21% | +$357K |
|
|
GNMK
2270
DELISTED
GenMark Diagnostics, Inc
GNMK
| $2.2M | ﹤0.01% |
339,100
+206,965
| +157% | +$1.46M |
|
2271
Greif Class B
GEF.B
$4.24B
| $2.2M | ﹤0.01% |
50,410
+1,200
| +2% | +$55.1K |
|
2272
International Seaways
INSW
$4.71B
| $2.2M | ﹤0.01% |
115,600
+105,100
| +1,001% | +$1.95M |
|
2273
Griffon
GFF
$4.8B
| $2.19M | ﹤0.01% |
129,500
+2,800
| +2% | +$47.9K |
|
|
HMNF
2274
DELISTED
HMN Financial Inc
HMNF
| $2.18M | ﹤0.01% |
103,700
+2,900
| +3% | +$63.1K |
|
|
HMHC
2275
DELISTED
Houghton Mifflin Harcourt Company
HMHC
| $2.18M | ﹤0.01% |
378,100
-66,000
| -15% | -$438K |
|
Similar funds
Jim Simons's Q2 2019 Portfolio in Review
As of Q2 2019, Jim Simons held 3,913 positions worth $114B, up 3.3% from $110B the previous quarter. Its ten largest holdings account for 9.1% of the portfolio.
Jim Simons's Q2 2019 filing shows 495 new, 1,847 increased, 1,145 reduced and 397 closed positions. Its largest new stake was Apple: 9,290,160 shares worth $460M. The largest sale was UnitedHealth, an estimated $307M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 17% a quarter earlier, followed by Technology and Financials.
- Jim Simons's largest Q2 2019 buy was Apple: 9,290,160 shares worth $460M.
- Jim Simons added most to Celgene Corp in Q2 2019, an estimated $391M increase.
- Jim Simons's biggest Q2 2019 reduction was Microsoft, cutting an estimated $230M.
- Jim Simons fully exited UnitedHealth in Q2 2019, selling an estimated $307M.
- Jim Simons's ten largest holdings make up 9.1% of its $114B portfolio in Q2 2019.
- Jim Simons opened 495 new positions and closed 397 in Q2 2019.
- Jim Simons's portfolio value rose 3.3% quarter-over-quarter to $114B.
Based on Renaissance Technologies's 13F filing for Q2 2019, filed 12 Aug 2019.